Anika Therapeutics (ANIK) Tops Q1 EPS by 27c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.40 +4.88%
Revenue Growth %: +5.9%
Financial Fact:
Interest income (expense), net: 93K
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: +5.9%
Financial Fact:
Interest income (expense), net: 93K
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.09, $0.27 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $40.5 million versus the consensus estimate of $41.55 million.
GUIDANCE:
Anika Therapeutics sees FY2024 revenue of $168-173 million, versus the consensus of $170.3 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 3c
- Personalis, Inc. (PSNL) Misses Q3 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
